Embassy Developments Reports Record Financial Performance Amid Market Updates

Embassy Developments Limited has announced its strongest ever quarterly financial performance, reporting pre-sales of ₹2,632 crore for Q4 FY26. While the company is managing ongoing legal proceedings regarding a contingent liability, it confirms that it remains financially sound and fully operational. The firm is actively working with stock exchanges regarding its current trading classification and remains focused on maintaining high standards of governance and growth momentum for its stakeholders.

Record-Breaking Financial Results

The company concluded the fiscal year 2026 with exceptional momentum, achieving its highest-ever quarterly pre-sales of ₹2,632 crore in Q4 (January-March), marking a significant 89% increase compared to the previous quarter. For the full fiscal year 2026, total pre-sales reached ₹4,631 crore, representing a robust 128% growth year-over-year.

Operational Highlights

Business operations remain strong, supported by the successful launch and market reception of several key projects, including Embassy Citadel in Worli and Embassy Verde 2 in Bengaluru. Additionally, the company secured RERA registration for Embassy Serenity in Alibaug (Phase I) during the final quarter. Collections also showed positive growth, reaching ₹577 crore in Q4 FY26, a 39% increase over the previous quarter, bringing the annual collection total to ₹1,721 crore.

Corporate Status and Outlook

Management has reiterated that the company is not subject to insolvency resolution processes and that the stay on previous legal orders remains in full force. Regarding a specific legal matter involving a contingent equity infusion obligation, the company maintains that it holds no debt-obligation, noting that the exposure of approximately ₹370 crore is minimal relative to its net equity base. The company continues to prioritize operational stability and remains committed to transparent communication with its shareholders.

Source: BSE

Previous Article

AstraZeneca Pharma India New Indication Approved for Calquence

Next Article

GAIL (India) Limited Corporate Bond Disclosure for FY 2025-26